Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Alumis Inc ALMS

Healthcare Biotechnology
Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2... see more

Current News (NDAQ:ALMS)

Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

GlobeNewswire 1 day ago

Alumis to Participate in Upcoming November Investor Conferences

GlobeNewswire 11 days ago

Alumis to Participate in Upcoming September Investor Conferences

GlobeNewswire August 29, 2025

Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire August 13, 2025

Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus

GlobeNewswire July 24, 2025

Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary

GlobeNewswire July 14, 2025

Alumis to Present at the Jefferies Global Healthcare Investor Conference

GlobeNewswire May 29, 2025

Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

GlobeNewswire May 29, 2025

Alumis Completes Merger with ACELYRIN

GlobeNewswire May 21, 2025
View More News ››

Opinion & Analysis (NDAQ:ALMS)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ALMS)

Using technical analysis for this stock.

It is signalling a big uptrend for shareholders today for this one,so good luck to all
coolfooldumbguy - March 25, 2025
View more Bullboard ››

ESGold Corp.

ESGold Corp.

ESGold Corp is a Canada-based, fully permitted, pre-production gold and silver mining company. The Company is in the process ...
View More »